Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.
| Revenue (TTM) | $201.83B |
| Gross Profit (TTM) | $53.35B |
| EBITDA | $8.71B |
| Operating Margin | 4.22% |
| Return on Equity | 11.50% |
| Return on Assets | 4.01% |
| Revenue/Share (TTM) | $923.29 |
| Book Value | $206.75 |
| Price-to-Book | 2.11 |
| Price-to-Sales (TTM) | 0.46 |
| EV/Revenue | 0.568 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 17.90% |
| Quarterly Revenue Growth (YoY) | 1.40% |
| Shares Outstanding | $216.87M |
| Float | $215.57M |
| % Insiders | 0.18% |
| % Institutions | 94.19% |
Volatility is currently expanding
Wall Street is punishing CVS Health (NYSE:CVS | CVS Price Prediction) for a plan to break up the pharmacy, benefits and insurance empire it spent years building, even after a strong quarter. CVS stock is at $80.
Does Elevance Health (ELV) have what it takes to be a top stock pick for momentum investors? Let's find out.
Investors need to pay close attention to ELV stock based on the movements in the options market lately.
Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?
Elevance Health raised its 2026 adjusted EPS guidance to at least $29, but the sustainability of its earnings recovery remains uncertain. Third-quarter adjusted EPS rose 15.9%, while nine-month operating gain declined 25.7%, highlighting the gap between improving earnings and underlying profitability. Health Benefits margins remain under pressure, particularly in Medicaid, despite improving medical cost trends and stronger quarterly results.
Elevance raised its 2026 earnings baseline to at least $26.75 per share. Carelon's cancer program reduced avoidable inpatient admissions by 15%.
Elevance Health (ELV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Elevance Health beats Q3 EPS estimate by 50% as Carelon grows despite declining medical membership, and lifts its 2026 underlying earnings baseline to $26.75.
Elevance Health NYSE: ELV raised its 2026 earnings outlook after reporting third-quarter adjusted diluted earnings per share of $6.99, exceeding the company's expectations as Medicaid, Medicare Advantage and Individual ACA businesses all performed better than anticipated.
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ELV and any ticker you trade — then tracks every position and per-strategy win rate.
